Share on Facebook Share on Twitter Email
Answers.com

testosterone

 
American Heritage Dictionary:

tes·tos·ter·one

(tĕs-tŏs'tə-rōn') pronunciation
n.
A white crystalline steroid hormone, C19H28O2, produced primarily in the testes and responsible for the development and maintenance of male secondary sex characteristics. It is also produced synthetically for use in medical treatment.

[TEST(IS) + STER(OL) + -ONE.]


Search unanswered questions...
Enter a question here...
Search: All sources Community Q&A Reference topics

Masculinizing sex hormone produced by the testes. It is responsible for the development of the male sex organs and secondary sex characteristics (e.g., facial hair, masculine musculature, deep voice, and male-pattern baldness). Testosterone can be manufactured by modifying other, less expensive steroids. It is used in the treatment of hypogonadism, undescended testes (cryptorchism), and certain cancers.

For more information on testosterone, visit Britannica.com.

Gale Encyclopedia of Cancer:

Testosterone

Top

Key Terms: Hormone, Postmenopausal.

Definition

Synthetic derivatives of the natural hormone testosterone are used to reduce the size of hormone-responsive tumors.

Purpose

Testosterone-related drugs are used to treat advanced disseminated breast cancer in women.

Description

Testosterone belongs to a class of hormones called androgens. These are male hormones responsible for the development of the male reproductive system and secondary male sexual characteristics such as voice depth and facial hair. Testosterone is normally produced by the testes in large quantities in men. It also occurs normally in smaller quantities in women.

Several man-made derivatives of testosterone are used to treat advanced disseminated breast cancer in women, especially when cancer has spread to the bones. The most common of these testosterone-like drugs are fluoxymesterone (Halotestin) and methyltestosterone (Testred). These androgens are used only in women who have late-stage breast cancer and who meet specific criteria. These criteria include:

  • The patient is postmenopausal.
  • The tumors have been shown to be hormone-dependent.
  • The tumors have spread, often to the bone, or recurred after other hormonal cancer treatments.

Using testosterone derivatives to treat breast cancer is a palliative treatment. This means that the treatment helps relieve symptoms but does not cure the cancer. These drugs are approved by the United States Food and Drug Administration (FDA), and their cost is usually covered by insurance.

Clinical trials are currently underway that involve the use of testosterone-related androgens in varying combinations with other drugs to treat advanced cancers. The selection of clinical trials changes constantly. Current information on the availability and location of clinical trials can be found at the following web sites:

  • National Cancer Institute. (800) 4-CANCER or .
  • National Institutes of Health Clinical Trials. .
  • Center Watch: A Clinical Trials Listing. .

Recommended Dosage

Dosage is individualized and depends on the patient's body weight and general health, as well as the other drugs she is taking and the way her cancer responds to hormones. Halotestin comes in tablets of 2 mg, 5 mg, or 10 mg. A standard dose of Halotestin for inoperable breast cancer is 10 to 40 mg in divided doses daily for several months. Tablets should be stored at room temperature. Testred comes in 10 mg capsules. A standard dose for women with advanced breast cancer is 50 to 200 mg daily.

Precautions

Women who take testosterone derivatives for advanced breast cancer are postmenopausal, so the usual precautions about avoiding pregnancy when receiving androgen therapy do not apply.

Side Effects

The most serious side effect of these drugs is hypercalcemia, a condition in which too much calcium circulates in the blood. This occurs because these drugs liberate calcium from bones. Calcium levels are monitored regularly, and the drug is discontinued if hypercalcemia occurs. Another serious (but less common) side effect is the development of tumors in the liver. Other side effects include deepening of the voice, development of facial hair and acne, fluid retention, and nausea.

Interactions

As with any course of treatment, patients should alert their physician to any prescription, over-the-counter, or herbal remedies they are taking in order to avoid harmful drug interactions. Patients should also mention if they are on a special diet, such as low salt or high protein. They should not take calcium supplements, since testosterone already has the potential to increase circulating calcium to dangerous levels.

Testosterone derivatives may interact with anticoagulant drugs (blood thinners) such as Coumadin.

—Tish Davidson, A.M.

The main male sex hormone. Testosterone is secreted by the testes throughout life, but there is some decline with age. To offset this decline and in the hope of retaining youthful virility, some older men take testosterone preparations (in the past, extra testosterone was sometimes obtained by eating testes of monkeys). Surprisingly, testosterone is also secreted in small amounts from the adrenal glands in women. This secretion increases after exercise but decreases with overtraining. Rapid weight loss may also lead to lower testosterone levels. High testosterone levels in females may interfere with some actions of female sex hormones, disrupting the menstrual cycle but reducing premenstrual stress. Low testosterone levels in males may reduce sexual desire. Low levels may also reduce a person's energy capacity by affecting the body's ability to store energy in the form of creatine phosphate and glycogen.

Testosterone has both androgenic (masculinizing) and anabolic (tissue-building) effects. It acts as an androgen by promoting the development of male secondary sexual characteristics. Its anabolic effects include stimulating muscle growth and reducing muscle degradation during training. Both help to improve muscle strength. Most users of synthetic testosterone do not wish to have the masculinizing effects. Therefore, synthetic analogues of testosterone are designed to emphasize the anabolic properties while minimizing the androgenic properties. These preparations can be harmful and have been linked to liver disease, tumour growth, breast development in men, and suppression of normal female hormones. Consequently, the use of testosterone and related drugs has been banned by the International Olympic Committee on the principle that athletes should not be allowed to sacrifice their health to obtain a competitive advantage. However, testosterone supplements do have their valid medical uses. For example, they are administered to some anorexics to help them build muscle mass and aid their recovery. See also anabolic steroids.

The most potent of the male steroid sex hormones, which are collectively known as androgens. It is produced by the interstitial (Leydig) cells of the testis, and acts locally to stimulate development of sperm, and via the circulating blood to promote male characteristics. However, in many target tissues testosterone must first be converted to 5α-dihydrotestosterone (DHT) before it is active.

— Saffron A. Whitehead

See sex hormones.

Drug Info:

Testosterone

Top

Brand names: Andro-L.A.®, Androderm®, AndroGel®, Depandrate™, Depo-Testosterone®, First®-Testosterone, First®-Testosterone MC, Striant™, Testa Span™, Testerone™, Testim™, Testoderm®, Testone CYP 200, Tostrelle™, Tostrex™, Virilon® Injection

Chemical formula:



Testosterone Topical gel

What is this medicine?

TESTOSTERONE (tes TOS ter one) is the main male hormone. It supports normal male traits such as muscle growth, facial hair, and deep voice. This gel is used in males to treat low testosterone levels.
 
This medicine may be used for other purposes; ask your health care provider or pharmacist if you have questions.

What should I tell my health care provider before I take this medicine?

They need to know if you have any of these conditions:
•breast cancer
•diabetes
•heart disease
•if a female partner is pregnant or trying to get pregnant
•kidney disease
•liver disease
•lung disease
•prostate cancer, enlargement
•an unusual or allergic reaction to testosterone, soy proteins, other medicines, foods, dyes, or preservatives
•pregnant or trying to get pregnant
•breast-feeding

How should I use this medicine?

This medicine is for external use only. This medicine is applied at the same time every day (preferably in the morning) to clean, dry, intact skin. If you take a bath or shower in the morning, apply the gel after the bath or shower. Follow the directions on the prescription label. Make sure that you are using your testosterone gel product correctly and applying it only to the appropriate skin area (see below). Allow the skin to dry a few minutes then cover with clothing to prevent others from coming in contact with the medicine on your skin. The gel is flammable. Avoid fire, flame, or smoking until the gel has dried. Wash your hands with soap and water after use.
 
For AndroGel Packets: Open the packet(s) needed for your dose. You can put the entire dose into your palm all at once or just a little at a time to apply. If you prefer, you can instead squeeze the gel directly onto the area you are applying it to. Apply on the shoulders, upper arm, or abdomen as directed. Do not apply to the scrotum or genitals. Be sure you use the correct total dose. It is best to wait 5 to 6 hours after application of the gel before showering or swimming.
 
For AndroGel 1%: Pump the dose into the palm of your hand. You can put the entire dose into your palm all at once or just a little at a time to apply. If you prefer, you can instead pump the gel directly onto the area you are applying it to. Apply on the shoulders, upper arm, or abdomen as directed. Do not apply to the scrotum or genitals. Be sure you use the correct total dose. It is best to wait for 5 to 6 hours after application of the gel before showering or swimming.
 
For AndroGel 1.62%: Pump the dose into the palm of your hand. Dispense one pump of gel at a time into the palm of your hand before applying it. If you prefer, you can instead pump the gel directly onto the area you are applying it to. Apply on the shoulders and upper arms as directed. Do not apply to other parts of the body including the abdomen or genitals. Be sure you use the correct total dose. It is best to wait 2 hours after application of the gel before washing, showering, or swimming.
 
For Testim: Open the tube(s) needed for your dose. Squeeze the gel from the tube into the palm of your hand. Apply on the shoulders or upper arms as directed. Do not apply to the scrotum, genitals, or abdomen. Be sure you use the correct total dose. Do not shower or swim for at least 2 hours after application of the gel.
 
For Fortesta: Use the multi-dose pump to pump the gel directly onto the area you are applying it to. Apply on the thighs as directed. Do not apply to the abdomen, penis, scrotum, shoulders or upper arms. Gently rub the gel onto the skin using your finger. Be sure you use the correct total dose. Do not shower or swim for at least 2 hours after application of the gel.
 
A special MedGuide will be given to you by the pharmacist with each prescription and refill. Be sure to read this information carefully each time.
 
Talk to your pediatrician regarding the use of this medicine in children. Special care may be needed.
 
Overdosage: If you think you have taken too much of this medicine contact a poison control center or emergency room at once.
NOTE: This medicine is only for you. Do not share this medicine with others.

What if I miss a dose?

If you miss a dose. take it as soon as you can. If it is almost time for your next dose, take only that dose. Do not take double or extra doses.

What may interact with this medicine?

•medicines for diabetes
•medicines that treat or prevent blood clots like warfarin
•oxyphenbutazone
•propranolol
•steroid medicines like prednisone or cortisone

This list may not describe all possible interactions. Give your health care provider a list of all the medicines, herbs, non-prescription drugs, or dietary supplements you use. Also tell them if you smoke, drink alcohol, or use illegal drugs. Some items may interact with your medicine.

What should I watch for while using this medicine?

Visit your doctor or health care professional for regular checks on your progress. They will need to check the level of testosterone in your blood.
 
This medicine can transfer from your body to others. If a person or pet comes in contact with the area where this medicine was applied to your skin, they may have a serious risk of side effects. If you cannot avoid skin-to-skin contact with another person, make sure the site where this medicine was applied is covered with clothing. If accidental contact happens, the skin of the person or pet should be washed right away with soap and water. Also, a female partner who is pregnant or trying to get pregnant should avoid contact with the gel or treated skin.
 
This medicine may affect blood sugar levels. If you have diabetes, check with your doctor or health care professional before you change your diet or the dose of your diabetic medicine.
 
This drug is banned from use in athletes by most athletic organizations.

What side effects may I notice from receiving this medicine?

Side effects that you should report to your doctor or health care professional as soon as possible:
•allergic reactions like skin rash, itching or hives, swelling of the face, lips, or tongue
•breast enlargement
•breathing problems
•changes in mood, especially anger, depression, or rage
•dark urine
•general ill feeling or flu-like symptoms
•light-colored stools
•loss of appetite, nausea
•nausea, vomiting
•right upper belly pain
•stomach pain
•swelling of ankles
•too frequent or persistent erections
•trouble passing urine or change in the amount of urine
•unusually weak or tired
•yellowing of the eyes or skin

Side effects that usually do not require medical attention (report to your doctor or health care professional if they continue or are bothersome):
•acne
•change in sex drive or performance
•hair loss
•headache

This list may not describe all possible side effects. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Where should I keep my medicine?

Keep out of the reach of children. This medicine can be abused. Keep your medicine in a safe place to protect it from theft. Do not share this medicine with anyone. Selling or giving away this medicine is dangerous and against the law.

Store at room temperature between 15 to 30 degrees C (59 to 86 degrees F). Keep closed until use. Protect from heat and light. This medicine is flammable. Avoid exposure to heat, fire, flame, and smoking. Throw away any unused medicine after the expiration date.

Last updated: 12/27/2004 11:22:00 AM

Important Disclaimer: The drug information provided here is for educational purposes only. It is intended to supplement, not substitute for, the diagnosis, treatment and advice of a medical professional. This drug information does not cover all possible uses, precautions, side effects and interactions. It should not be construed to indicate that this or any drug is safe for you. Consult your medical professional for guidance before using any prescription or over the counter drugs.


The main androgen (male sex hormone). It is available as a variety of esters (testosterone enantate, propionate, and undecanoate) for the treatment of underdevelopment of the testes or as replacement therapy in castrated men. It can also be used in postmenopausal women as an adjunct in hormone replacement therapy and to treat women with low libido with surgically induced menopause. Testosterone is available, on prescription only, as capsules, an intramuscular injection, a depot implant, a topical gel, or transdermal (skin) patches.

Side effects:
include excessive frequency and duration of penile erections, sodium and fluid retention, increased bone growth, enlargement of the prostate, reduced production of sperm, headache, depression, anxiety, generalized tingling sensations, gastrointestinal bleeding, nausea, jaundice, changes in libido, abnormal hair growth in women, male pattern baldness, and acne.

Precautions:
testosterone should not be taken by men with cancer of the breast or prostate or by women who are pregnant or breastfeeding. It should be used with caution in people who have heart, liver, or kidney disease, in elderly men and prepubertal boys, and in people who suffer from high blood pressure, epilepsy, or migraine.

Interactions with other drugs:

Anticoagulants testosterone enhances the effects of warfarin, acenocoumarol, and phenindione.
Antidiabetic drugs: testosterone may increase their effects in lowering blood-sugar concentrations.

Proprietary preparations:
Andropatch (transdermal patches); Intrinsa (skin patches); Nebido (injection); Restandol (capsules); Striant sustained release (= modified release)(modified-release buccal tablets); Sustanon 250 (depot formulation); Testim (gel); Testogel (gel); Testosterone Enantate (injection); Testosterone Implant; Tostran (gel); Virormone (injection and patches).

Previous:terpineol, terlipressin, teriparatide
Next:tetrabenazine, tetracaine, tetracosactide acetate

An Anabolic Androgenic Steroid occurring naturally in both males and females (it is secreted by the adrenal cortex and ovaries in small amounts). It is the main male sex hormone secreted by the testes. In males, it induces and maintains the changes that take place at puberty. The testes continue to produce testosterone throughout life, though there is some decline with age. Synthetic testosterone preparations have been designed to emphasize anabolic effects, while minimizing androgenic properties. Testosterone and related drugs are in the 2005 Prohibited List of the World Anti-Doping Code. Testosterone is usually excreted in the same amounts as epitestosterone. Consequently, the ratio of testosterone to epitestosterone in the urine (the T/E ratio) is used by anti-doping agencies as an indicator of testosterone misuse. According to the 2005 World Anti-Doping Code, if a ‘laboratory has reported the presence of a T/E ratio of greater than four (4) to one (1) in the urine, further investigation is obligatory in order to determine whether the ratio is due to a physiological or pathological condition, except if the laboratory reports an Adverse Analytical Finding based on any reliable analytical method showing that the Prohibited Substance is of exogenous origin.'

Testosterone
Testosterone

Columbia Encyclopedia:

testosterone

Top
testosterone (tĕstŏs'tərōn), principal androgen, or male sex hormone. One of the group of compounds known as anabolic steroids, testosterone is secreted by the testes (see testis) but is also synthesized in small quantities in the ovaries, cortices of the adrenal glands, and placenta, usually from cholesterol. Testosterone is necessary in the fetus for the development of male external genitalia; increased levels of testosterone at puberty are responsible for further growth of male genitalia and for the development and maintenance of male secondary sex characteristics such as facial hair and voice changes. Testosterone also stimulates protein synthesis and accounts for the greater muscular development of the male (see metabolism). For many years, synthetic steroids similar to testosterone have been used by athletes with the goal of improving performance, although recent medical research has shown that these drugs may have a wide range of harmful side effects.


(tes-tos-tuh-rohn)

A male hormone that governs secondary sex characteristics. It is produced in the testes.


4-androsten-17β-ol-3-one; the principal and most potent androgen. It is formed from androstenedione by 3α(17β)-hydroxysteroid dehydrogenase (NAD+) (EC 1.1.1.239), in Leydig cells of the testis. Testosterone is responsible during embryonic development for virilization, and promotes and maintains male secondary sex characteristics throughout life. It is also synthesized in the ovary from which some is secreted into the blood, but most is converted to estradiol. Its actions are in large part mediated by dihydrotestosterone, to which it is converted in target cells. See also androgen receptor.





Previous:testis, testicular feminization, testicular
Next:tetO, tetanus, tetanus toxin

The most important male sex hormone (androgen) produced by the Leydig cells of the testes in response to luteinizing hormone (LH) secreted by the pituitary. Its chief function is to stimulate the development of the male reproductive organs and the secondary sex characters, such as the crest. It is necessary for the appearance of normal male sexual behavior. It encourages growth of bone and muscle, and helps maintain muscle strength. It is occasionally secreted in large amounts also by granulosa–theca cell tumors of the ovary, especially in mares.

  • t. cyclopentylpropionate, t. cypionate, t. propionate — esters with a long period of activity.
  • t.-responsive dermatosis — a bilaterally symmetrical alopecia, primarily affecting the flanks, ventral abdomen and caudomedial aspect of the thighs of male dogs. The cause is believed to be hypotestosteronism.
Random House Word Menu:

categories related to 'testosterone'

Top
Random House Word Menu by Stephen Glazier
For a list of words related to testosterone, see:

Wikipedia on Answers.com:

Testosterone

Top
Testosterone
Systematic (IUPAC) name
(8R,9S,10R,13S,14S,17S)- 17-hydroxy-10,13-dimethyl- 1,2,6,7,8,9,11,12,14,15,16,17- dodecahydrocyclopenta[a]phenanthren-3-one
Clinical data
Trade names Androderm, Delatestryl
AHFS/Drugs.com monograph
Pregnancy cat. X (USA), Teratogenic effects
Legal status Schedule III (USA)
Schedule IV (Canada)
Routes Intramuscular injection, transdermal (cream, gel, or patch), sub-'Q' pellet
Pharmacokinetic data
Bioavailability low (due to extensive first pass metabolism)
Metabolism Liver, Testis and Prostate
Half-life 2–4 hours
Excretion Urine (90%), feces (6%)
Identifiers
CAS number 58-22-0 YesY
57-85-2 (propionate ester)
ATC code G03BA03
PubChem CID 6013
DrugBank DB00624
ChemSpider 5791 YesY
UNII 3XMK78S47O YesY
KEGG D00075 YesY
ChEBI CHEBI:17347 N
ChEMBL CHEMBL386630 YesY
Chemical data
Formula C19H28O2 
Mol. mass 288.42
SMILES eMolecules & PubChem
Physical data
Melt. point 155 °C (311 °F)
Spec. rot +110,2°
SEC Combust −11080 kJ/mol
 N(what is this?)  (verify)

Testosterone is a steroid hormone from the androgen group and is found in mammals, reptiles,[1] birds,[2] and other vertebrates. In mammals, testosterone is primarily secreted in the testes of males and the ovaries of females, although small amounts are also secreted by the adrenal glands. It is the principal male sex hormone and an anabolic steroid.

In men, testosterone plays a key role in the development of male reproductive tissues such as the testis and prostate as well as promoting secondary sexual characteristics such as increased muscle, bone mass, and the growth of body hair.[3] In addition, testosterone is essential for health and well-being[4] as well as the prevention of osteoporosis.[5]

On average, an adult human male body produces about ten times more testosterone than an adult human female body, but females are more sensitive to the hormone.[6]

Testosterone is observed in most vertebrates. Fish make a slightly different form called 11-ketotestosterone.[7] Its counterpart in insects is ecdysone.[8] These ubiquitous steroids suggest that sex hormones have an ancient evolutionary history.[9]

Contents

Physiological effects

In general, androgens promote protein synthesis and growth of those tissues with androgen receptors. Testosterone effects can be classified as virilizing and anabolic, though the distinction is somewhat artificial, as many of the effects can be considered both. Testosterone is anabolic, meaning it builds up bone and muscle mass.

Testosterone effects can also be classified by the age of usual occurrence. For postnatal effects in both males and females, these are mostly dependent on the levels and duration of circulating free testosterone.

Prenatal

The prenatal androgen effects occur during two different stages. Between 4 and 6 weeks of the gestation.

During the 2nd trimester androgen level is associated with Gender identity[10] This period affects the femininization or masculinization of the fetus and can be a better predictor of feminine or mascular behaviours such as sex typed behaviour than an adult's own levels. A mother's own testosterone level influences behavior more than the daughters's testosterone level during pregnancy.[11]

Early infancy

Early infancy androgen effects are the least understood. In the first weeks of life for male infants, testosterone levels rise. The levels remain in a pubertal range for a few months, but usually reach the barely detectable levels of childhood by 4–6 months of age.[12][13] The function of this rise in humans is unknown. It has been speculated that "brain masculinization" is occurring since no significant changes have been identified in other parts of the body.[14][citation needed] Surprisingly, the male brain is masculinized by testosterone being aromatized into estrogen, which crosses the blood-brain barrier and enters the male brain, whereas female fetuses have alpha-fetoprotein which binds up the estrogen so that female brains are not affected.[15]

Pre-peripubertal

Pre- Peripubertal effects are the first observable effects of rising androgen levels at the end of childhood, occurring in both boys and girls.

Pubertal

Pubertal effects begin to occur when androgen has been higher than normal adult female levels for months or years. In males, these are usual late pubertal effects, and occur in women after prolonged periods of heightened levels of free testosterone in the blood.

Adult

Adult testosterone effects are more clearly demonstrable in males than in females, but are likely important to both sexes. Some of these effects may decline as testosterone levels decrease in the later decades of adult life.

Reference ranges for blood tests, showing adult male testosterone levels in light blue at center-left.
  • Testosterone is necessary for normal sperm development. It activates genes in Sertoli cells, which promote differentiation of spermatogonia.
  • Regulates acute HPA (Hypothalamic–pituitary–adrenal axis) response under dominance challenge[17]
  • Mental and physical energy
  • Maintenance of muscle trophism
  • Testosterone regulates the population of thromboxane A2 receptors on megakaryocytes and platelets and hence platelet aggregation in humans[18][19]
  • Testosterone does not cause or produce deleterious effects on prostate cancer. In people who have undergone testosterone deprivation therapy, testosterone increases beyond the castrate level have been shown to increase the rate of spread of an existing prostate cancer.[20][21][22]
  • Recent studies have shown conflicting results concerning the importance of testosterone in maintaining cardiovascular health.[23][24] Nevertheless, maintaining normal testosterone levels in elderly men has been shown to improve many parameters which are thought to reduce cardiovascular disease risk, such as increased lean body mass, decreased visceral fat mass, decreased total cholesterol, and glycemic control.[25]
  • Under dominance challenge, may play a role in the regulation of the fight-or-flight response[26]
  • Falling in love decreases men's testosterone levels while increasing women's testosterone levels. It is speculated that these changes in testosterone result in the temporary reduction of differences in behavior between the sexes.[27] It has been found that when the testosterone and endorphins in the ejaculated semen meet the cervical wall after sexual intercourse, females receive a spike in testosterone, endorphin, and oxytocin levels, and males after orgasm during copulation experience an increase in endorphins and a marked increase in oxytocin levels. This adds to the hospitable physiological environment in the female internal reproductive tract for conceiving, and later for nurturing the conceptus in the pre-embryonic stages, and stimulates feelings of love, desire, and paternal care in the male (this is the only time male oxytocin levels rival a female's).[28]
  • Recent studies suggest that testosterone levels play a major role in risk-taking during financial decisions.[29][30]
  • The administration of testosterone makes men selfish and more likely to punish others for being selfish towards them.[31]
  • Fatherhood also decreases testosterone levels in men, suggesting that the resulting emotional and behavioral changes promote paternal care.[32]
  • Men whose testosterone levels are slightly above average are less likely to have high blood pressure, less likely to experience a heart attack, less likely to be obese, and less likely to rate their own health as fair or poor. However, high testosterone men are more likely to report one or more injuries, more likely to consume five or more alcoholic drinks in a day, more likely to have had a sexually transmitted infection, and more likely to smoke.[33]

Brain

As testosterone affects the entire body (often by enlarging; males have bigger hearts, lungs, liver, etc.), the brain is also affected by this "sexual" differentiation;[10] the enzyme aromatase converts testosterone into estradiol that is responsible for masculinization of the brain in male mice. In humans, masculinization of the fetal brain appears, by observation of gender preference in patients with congenital diseases of androgen formation or androgen receptor function, to be associated with functional androgen receptors.[34]

There are some differences between a male and female brain (possibly the result of different testosterone levels), one of them being size: the male human brain is, on average, larger.[35] In a Danish study from 2003, men were found to have a total myelinated fiber length of 176,000 km at the age of 20, whereas in women the total length was 149,000 km (approx. 15% less).[36]

A study conducted in 1996 found no immediate short term effects on mood or behavior from the administration of supraphysiologic doses of testosterone for 10 weeks on 43 healthy men.[16] Another study found a correlation between testosterone and risk tolerance in career choice among women.[37]

Literature suggests that attention, memory, and spatial ability are key cognitive functions affected by testosterone in humans. Preliminary evidence suggests that low testosterone levels may be a risk factor for cognitive decline and possibly for dementia of the Alzheimer’s type,[38][39] a key argument in life extension medicine for the use of testosterone in anti-aging therapies. Much of the literature, however, suggests a curvilinear or even quadratic relationship between spatial performance and circulating testosterone,[40] where both hypo- and hypersecretion (deficient- and excessive-secretion) of circulating androgens have negative effects on cognition and cognitively modulated aggressivity, as detailed above.[citation needed]

Contrary to what has been postulated in outdated studies and by certain sections of the media, aggressive behaviour is not typically seen in hypogonadal men who have their testosterone replaced adequately to the eugonadal/normal range.[citation needed] In fact, aggressive behaviour has been associated with hypogonadism and low testosterone levels and it would seem as though supraphysiological and low levels of testosterone and hypogonadism cause mood disorders and aggressive behaviour,[citation needed] with eugondal/normal testosterone levels being important for mental well-being. Testosterone depletion is a normal consequence of aging in men. One possible consequence of this could be an increased risk for the development of Alzheimer’s disease.[41][42]

Aggression

The positive correlation between testosterone levels and aggression in humans has been demonstrated in many studies, but about half of studies fail to find a link.[43] While testosterone itself is not shown to be the direct cause of aggression in males, the testosterone derivative estradiol is known to correlate with aggression in male mice.[44]

Fatherhood

Fatherhood has been demonstrated to lower men's testosterone levels.[45]

Ethnic differences

Different ethnic groups have different incidences of prostate cancer. Differences in sex hormones including testosterone have been suggested as an explanation for these differences. A 2009 study found ethnical differences between blacks and whites in the testosterone to sex hormone binding globulin ratio in blood from the umbilical cord in infants.[46][47][48]

Medical uses

The original and primary use of testosterone is for the treatment of males who have too little or no natural endogenous testosterone production—males with hypogonadism. Appropriate use for this purpose is legitimate hormone replacement therapy (testosterone replacement therapy [TRT]), which maintains serum testosterone levels in the normal range.

However, over the years, as with every hormone, testosterone or other anabolic steroids has also been given for many other conditions and purposes besides replacement, with varying success but higher rates of side effects or problems. Examples include reducing infertility, correcting lack of libido or erectile dysfunction, correcting osteoporosis, encouraging penile enlargement, encouraging height growth, encouraging bone marrow stimulation and reversing the effects of anemia, and even appetite stimulation. By the late 1940s testosterone was being touted as an anti-aging wonder drug (e.g., see Paul de Kruif's The Male Hormone).[49] Decline of testosterone production with age has led to interest in androgen replacement therapy.[50]

To take advantage of its virilizing effects, testosterone is often administered to transsexual men as part of the hormone replacement therapy, with a "target level" of the normal male testosterone level. Like-wise, transsexual women are sometimes prescribed anti-androgens to decrease the level of testosterone in the body and allow for the effects of estrogen to develop.

Testosterone patches are effective at treating low libido in post-menopausal women.[51] Low libido may also occur as a symptom or outcome of hormonal contraceptive use. Women may also use testosterone therapies to treat or prevent loss of bone density, muscle mass and to treat certain kinds of depression and low energy state. Women on testosterone therapies may experience an increase in weight without an increase in body fat due to changes in bone and muscle density. Most undesired effects of testosterone therapy in women may be controlled by hair-reduction strategies, acne prevention, etc. There is a theoretical risk that testosterone therapy may increase the risk of breast or gynaecological cancers, and further research is needed to define any such risks more clearly.[51]

Hormone replacement therapy

Testosterone levels decline gradually with age in human beings. The clinical significance of this decrease is debated (see andropause). There is disagreement about when to treat aging men with testosterone replacement therapy. The American Society of Andrology's position is that "testosterone replacement therapy in aging men is indicated when both clinical symptoms and signs suggestive of androgen deficiency and decreased testosterone levels are present."[52] The American Association of Clinical Endocrinologists says "Hypogonadism is defined as a free testosterone level that is below the lower limit of normal for young adult control subjects. Previously, age-related decreases in free testosterone were once accepted as normal. Currently, they are not considered normal. Patients with low-normal to subnormal range testosterone levels warrant a clinical trial of testosterone."[53]

There is not total agreement on the threshold of testosterone value below which a man would be considered hypogonadal. (Currently there are no standards as to when to treat women.) Testosterone can be measured as "free" (that is, bioavailable and unbound) or more commonly, "total" (including the percentage which is chemically bound and unavailable). In the United States, male total testosterone levels below 300 ng/dL from a morning serum sample are generally considered low.[54] Identification of inadequate testosterone in an aging male by symptoms alone can be difficult.

Replacement therapy can take the form of injectable depots, transdermal patches and gels, subcutaneous pellets, and oral therapy. Adverse effects of testosterone supplementation include minor side effects such as acne and oily skin, and more significant complications such as increased hematocrit which can require venipuncture in order to treat, exacerbation of sleep apnea and acceleration of pre-existing prostate cancer growth in individuals who have undergone androgen deprivation. Another adverse effect may be significant hair loss and/or thinning of the hair. This may be prevented with Propecia (Finasteride), which blocks DHT (a byproduct of testosterone in the body), during treatment. Exogenous testosterone also causes suppression of spermatogenesis and can lead to infertility.[55] It is recommended that physicians screen for prostate cancer with a digital rectal exam and PSA (prostate specific antigen) level before starting therapy, and monitor hematocrit and PSA levels closely during therapy.

Benefits

Appropriate testosterone therapy may improve the management of type 2 diabetes.[56] Low testosterone also brings with it an increased risk for the development of Alzheimer's disease.[41][42] A small trial in 2005 showed mixed results in using testosterone to combat the effects of aging.[57]

Large scale trials to assess the efficiency and long-term safety of testosterone are still lacking.[58]

Adverse effects

Exogenous testosterone supplementation comes with a number of health risks. Fluoxymesterone and methyltestosterone are synthetic derivatives of testosterone. Methyltestosterone and Fluoxymesterone are no longer prescribed by physicians given their poor safety record, and testosterone replacement in men does have a very good safety record as evidenced by over sixty years of medical use in hypogonadal men.

A 2006 article in Official Journal of the American Urological Association – The Journal of Urology pointed out that: Prostate cancer may become clinically apparent within months to a few years after the initiation of testosterone treatment. [...] Physicians prescribing testosterone supplementation and patients receiving it should be cognizant of this risk, and serum PSA testing and digital rectal examination should be performed frequently during treatment.[citation needed]

Athletic use

Testosterone can be used by an athlete in order to improve performance, but it is considered to be a form of doping in most sports. There are several application methods for testosterone, including intramuscular injections, transdermal gels and patches, and implantable pellets.

Anabolic steroids (including testosterone) have also been taken to enhance muscle development, strength, or endurance. They do so directly by increasing the muscles' protein synthesis. As a result, muscle fibers become larger and repair faster than the average person's. After a series of scandals and publicity in the 1980s (such as Ben Johnson's improved performance at the 1988 Summer Olympics), prohibitions of anabolic steroid use were renewed or strengthened by many sports organizations. Testosterone and other anabolic steroids were designated a "controlled substance" by the United States Congress in 1990, with the Anabolic Steroid Control Act.[59] The use is seen as being a seriously problematic issue in modern sport, particularly given the lengths to which athletes and professional laboratories go to in trying to conceal such abuse from sports regulators. Steroid abuse once again came into the spotlight recently as a result of the Chris Benoit double murder-suicide in 2007, and the media frenzy surrounding it – however, there has been no evidence indicating steroid use as a contributing factor.

Detection of abuse

A number of methods for detecting testosterone use by athletes have been employed, most based on a urine test. These include the testosterone/epitestosterone ratio (normally less than 6), the testosterone/luteinizing hormone ratio and the carbon-13 / carbon-12 ratio (pharmaceutical testosterone contains less carbon-13 than endogenous testosterone). In some testing programs, an individual's own historical results may serve as a reference interval for interpretation of a suspicious finding. Another approach being investigated is the detection of the administered form of testosterone, usually an ester, in hair.[60][61][62][63]

Routes of administration

Vial of testosterone for intramuscular injection

There are many routes of administration for testosterone. Forms of testosterone for human administration currently available include injectable (such as testosterone cypionate or testosterone enanthate in oil),[64] oral, buccal,[65] transdermal skin patches, transdermal creams, gels,[66][67] and implantable pellets.[68] Roll-on methods and nasal sprays are currently under development.

Biochemistry

Biosynthesis

Human steroidogenesis, showing testosterone near bottom.

Like other steroid hormones, testosterone is derived from cholesterol (see figure to the right).[69] The first step in the biosynthesis involves the oxidative cleavage of the sidechain of cholesterol by CYP11A, a mitochondrial cytochrome P450 oxidase with the loss of six carbon atoms to give pregnenolone. In the next step, two additional carbon atoms are removed by the CYP17A enzyme in the endoplasmic reticulum to yield a variety of C19 steroids.[70] In addition, the 3-hydroxyl group is oxidized by 3-β-HSD to produce androstenedione. In the final and rate limiting step, the C-17 keto group androstenedione is reduced by 17-β hydroxysteroid dehydrogenase to yield testosterone.

The largest amounts of testosterone (>95%) are produced by the testes in men.[3] It is also synthesized in far smaller quantities in women by the thecal cells of the ovaries, by the placenta, as well as by the zona reticularis of the adrenal cortex and even skin[71] in both sexes. In the testes, testosterone is produced by the Leydig cells.[72] The male generative glands also contain Sertoli cells which require testosterone for spermatogenesis. Like most hormones, testosterone is supplied to target tissues in the blood where much of it is transported bound to a specific plasma protein, sex hormone binding globulin (SHBG).

Regulation

Hypothalamic-pituitary-testicular axis

In males, testosterone is primarily synthesized in Leydig cells. The number of Leydig cells in turn is regulated by luteinizing hormone (LH) and follicle stimulating hormone (FSH). In addition, the amount of testosterone produced by existing Leydig cells is under the control of LH which regulates the expression of 17-β hydroxysteroid dehydrogenase.[73]

The amount of testosterone synthesized is regulated by the hypothalamic-pituitary-testicular axis (see figure to the right).[74] When testosterone levels are low, gonadotropin-releasing hormone (GnRH) is released by the hypothalamus which in turn stimulates the pituitary gland to release FSH and LH. These later two hormones stimulate the testis to synthesize testosterone. Finally increasing levels of testosterone through a negative feedback loop act on the hypothalamus and pituitary to inhibit the release of GnRH and FSH/LH respectively.

Environmental factors affecting testosterone levels include:

  • Weight loss makes fat men more masculine. Fat cells synthesise the enzyme aromatase which converts testosterone, the male sex hormone, into estradiol, the female sex hormone.[75]
  • The hormone vitamin D in levels of 400-1000 IU (10-25 mcg) raise testosterone level.[76]
  • Zinc deficiency lowers testosterone levels[77] but over supplementation has no effect on serum testosterone.[78]
  • Magnesium raise free testosterone according to studies.
  • Implicit power motivation[clarification needed] predicts an increased testosterone release in men.[79]
  • Aging reduces testosterone release.[80]
  • Hypogonadism
  • Sleep (REM dream) increases nocturnal testosterone levels.[81]
  • Resistance training increases testosterone levels,[82] however, in older men, that increase can be avoided by protein ingestion.[83]
  • Licorice. The active ingredient in licorice root, glycyrrhizinic acid has been linked to small, clinically non-significant decreases in testosterone levels.[84] In contrast, a more recent study found that licorice administration produced a substantial testosterone decrease in a small, female-only sample.[85]
  • Natural or man-made antiandrogens including spearmint tea reduce testosterone levels.[86][87][88]

Metabolism

Approximately 7% of testosterone is reduced to 5α-dihydrotestosterone (DHT) by the cytochrome P450 enzyme 5α-reductase,[89] an enzyme highly expressed in male accessory sex organs and hair follicles.[3] Approximately 0.3% of testosterone is converted into estradiol by aromatase (CYP19A1)[90] an enzyme expressed in the brain, liver, and adipose tissues.[3]

DHT is a more potent form of testosterone while estradiol has completely different activities (feminization) compared to testosterone (masculinization). Finally testosterone and DHT may be deactivated or cleared by enzymes that hydroxylate at the 6, 7, 15 or 16 positions.[91]

Mechanism of action

The effects of testosterone in humans and other vertebrates occur by way of two main mechanisms: by activation of the androgen receptor (directly or as DHT), and by conversion to estradiol and activation of certain estrogen receptors.[92][93]

Free testosterone (T) is transported into the cytoplasm of target tissue cells, where it can bind to the androgen receptor, or can be reduced to 5α-dihydrotestosterone (DHT) by the cytoplasmic enzyme 5-alpha reductase. DHT binds to the same androgen receptor even more strongly than testosterone, so that its androgenic potency is about 5 times that of T.[94] The T-receptor or DHT-receptor complex undergoes a structural change that allows it to move into the cell nucleus and bind directly to specific nucleotide sequences of the chromosomal DNA. The areas of binding are called hormone response elements (HREs), and influence transcriptional activity of certain genes, producing the androgen effects.

Androgen receptors occur in many different vertebrate body system tissues, and both males and females respond similarly to similar levels. Greatly differing amounts of testosterone prenatally, at puberty, and throughout life account for a share of biological differences between males and females.

The bones and the brain are two important tissues in humans where the primary effect of testosterone is by way of aromatization to estradiol. In the bones, estradiol accelerates maturation of cartilage into bone, leading to closure of the epiphyses and conclusion of growth. In the central nervous system, testosterone is aromatized to estradiol. Estradiol rather than testosterone serves as the most important feedback signal to the hypothalamus (especially affecting LH secretion)[citation needed]. In many mammals, prenatal or perinatal "masculinization" of the sexually dimorphic areas of the brain by estradiol derived from testosterone programs later male sexual behavior[citation needed].

The human hormone testosterone is produced in greater amounts by males, and less by females. The human hormone estrogen is produced in greater amounts by females, and less by males. Testosterone causes the appearance of masculine traits (i.e., deepening voice, pubic and facial hairs, muscular build, etc.) Like men, women rely on testosterone to maintain libido, bone density and muscle mass throughout their lives. In men, inappropriately high levels of estrogens lower testosterone, decrease muscle mass, stunt growth in teenagers, introduce gynecomastia, increase feminine characteristics (however as excess estrogen causes higher levels of testosterone to be manufactured to DHT which produces strong masculine secondary traits and acceleration of the aging process in men), and severely Increases susceptibility to prostate cancer, reduces libido and causes erectile dysfunction and can cause excessive sweating and hot flushes[citation needed]. However, an appropriate amount of estrogens is required in the male in order to ensure well-being, bone density, libido, erectile function, etc.[citation needed]

Synthetic analogs

A number of synthetic analogs of testosterone have been developed with improved bioavailability and metabolic half life relative to testosterone. Many of these analogs have an alkyl group introduced at the C-17 position in order to prevent conjugation and hence improve oral bioavailability. These are the so-called “17-aa” (17-alkyl androgen) family of androgens such as fluoxymesterone and methyltestosterone.

Related drugs

Some drugs indirectly target testosterone as a way of treating certain conditions. For example, 5-alpha-reductase inhibitors such as finasteride inhibits the conversion of testosterone into dihydrotestosterone (DHT), a metabolite which is more potent than testosterone.[95] These 5-alpha-reductase inhibitors have been used to treat various conditions associated with androgens, such as androgenetic alopecia (male-pattern baldness), hirsutism, benign prostatic hyperplasia (BPH), and prostate cancer.[95] Alternatively GnRH antagonists bind to GnRH receptors in the pituitary gland, blocking the release of luteinising hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary.[96] In men, the reduction in LH subsequently leads to rapid suppression of testosterone release from the testes. GnRH antagonists have been used for the treatment of prostate cancer.

Insufficiency

Testosterone insufficiency (also termed hypotestosteronism or hypotestosteronemia) is an abnormally low testosterone production. It may occur because of testicular dysfunction (primary hypogonadism) or hypothalamic-pituitary dysfunction (secondary hypogonadism) and may be congenital or acquired.[97] An acquired form of hypotestosteronism is a decline in testosterone levels that occurs by aging, sometimes being called "andropause" in men, as a comparison to the decline in estrogen that comes with menopause in women.

History

A testicular action was linked to circulating blood fractions – now understood to be a family of androgenic hormones – in the early work on castration and testicular transplantation in fowl by Arnold Adolph Berthold (1803–1861).[98] Research on the action of testosterone received a brief boost in 1889, when the Harvard professor Charles-Édouard Brown-Séquard (1817–1894), then in Paris, self-injected subcutaneously a “rejuvenating elixir” consisting of an extract of dog and guinea pig testicle. He reported in The Lancet that his vigor and feeling of well-being were markedly restored but, predictably, the effects were transient[99] (and likely based on a placebo effect), and Brown-Séquard’s hopes for the compound were dashed. Suffering the ridicule of his colleagues, his work on the mechanisms and effects of androgens in human beings was abandoned by Brown-Séquard and succeeding generations of biochemists for nearly 40 years.

The trail remained cold until the University of Chicago’s Professor of Physiologic Chemistry, Fred C. Koch, established easy access to a large source of bovine testicles—the Chicago stockyards—and to students willing to endure the ceaseless toil of extracting their isolates. In 1927, Koch and his student, Lemuel McGee, derived 20 mg of a substance from a supply of 40 pounds of bovine testicles that, when administered to castrated roosters, pigs and rats, remasculinized them.[100] The group of Ernst Laqueur at the University of Amsterdam purified testosterone from bovine testicles in a similar manner in 1934, but isolation of the hormone from animal tissues in amounts permitting serious study in humans was not feasible until three European pharmaceutical giants—Schering (Berlin, Germany), Organon (Oss, Netherlands) and Ciba (Basel, Switzerland)—began full-scale steroid research and development programs in the 1930s.

Leopold Ruzicka

The Organon group in the Netherlands were the first to isolate the hormone, identified in a May 1935 paper "On Crystalline Male Hormone from Testicles (Testosterone)".[101] They named the hormone testosterone, from the stems of testicle and sterol, and the suffix of ketone. The structure was worked out by Schering’s Adolf Butenandt.[102][103]

The chemical synthesis of testosterone from cholesterol was achieved in August that year by Butenandt and Hanisch.[104] Only a week later, the Ciba group in Zurich, Leopold Ruzicka (1887–1976) and A. Wettstein, published their synthesis of testosterone.[105] These independent partial syntheses of testosterone from a cholesterol base earned both Butenandt and Ruzicka the joint 1939 Nobel Prize in Chemistry.[103][106] Testosterone was identified as 17β-hydroxyandrost-4-en-3-one (C19H28O2), a solid polycyclic alcohol with a hydroxyl group at the 17th carbon atom. This also made it obvious that additional modifications on the synthesized testosterone could be made, i.e., esterification and alkylation.

The partial synthesis in the 1930s of abundant, potent testosterone esters permitted the characterization of the hormone’s effects, so that Kochakian and Murlin (1936) were able to show that testosterone raised nitrogen retention (a mechanism central to anabolism) in the dog, after which Allan Kenyon’s group[107] was able to demonstrate both anabolic and androgenic effects of testosterone propionate in eunuchoidal men, boys, and women. The period of the early 1930s to the 1950s has been called "The Golden Age of Steroid Chemistry",[108] and work during this period progressed quickly. Research in this golden age proved that this newly synthesized compound—testosterone—or rather family of compounds (for many derivatives were developed from 1940 to 1960), was a potent multiplier of muscle, strength, and well-being.[49]

Western trends

Recent analysis shows average testosterone levels receding in men of all ages.[109][110] Several theories from increases in obesity to exposure to endocrine disruptors have been proposed as an explanation for this reduction.[111]

References

  1. ^ Cox RM, John-Alder HB (December 2005). "Testosterone has opposite effects on male growth in lizards (Sceloporus spp.) with opposite patterns of sexual size dimorphism". J. Exp. Biol. 208 (Pt 24): 4679–87. doi:10.1242/jeb.01948. PMID 16326949. 
  2. ^ Reed WL, Clark ME, Parker PG, Raouf SA, Arguedas N, Monk DS, Snajdr E, Nolan V, Ketterson ED (May 2006). "Physiological effects on demography: a long-term experimental study of testosterone's effects on fitness". Am. Nat. 167 (5): 667–83. doi:10.1086/503054. PMID 16671011. Lay summary – ScienceDaily. 
  3. ^ a b c d Mooradian AD, Morley JE, Korenman SG (February 1987). "Biological actions of androgens". Endocr. Rev. 8 (1): 1–28. doi:10.1210/edrv-8-1-1. PMID 3549275. 
  4. ^ Bassil N, Alkaade S, Morley JE (June 2009). "The benefits and risks of testosterone replacement therapy: a review". Ther Clin Risk Manag 5 (3): 427–48. PMC 2701485. PMID 19707253. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2701485. 
  5. ^ Tuck SP, Francis RM (2009). "Testosterone, bone and osteoporosis". Front Horm Res. Frontiers of Hormone Research 37: 123–32. doi:10.1159/000176049. ISBN 978-3-8055-8622-1. PMID 19011293. 
  6. ^ Dabbs M, Dabbs JM (2000). Heroes, rogues, and lovers: testosterone and behavior. New York: McGraw-Hill. ISBN 0-07-135739-4. 
  7. ^ Nelson, Randy F. (2005). An introduction to behavioral endocrinology. Sunderland, Mass: Sinauer Associates. p. 143. ISBN 0-87893-617-3. 
  8. ^ De Loof A, Arnold (October 2006). "Ecdysteroids: the overlooked sex steroids of insects? Males: the black box". Insect Science 13 (5): 325–338. doi:10.1111/j.1744-7917.2006.00101.x. 
  9. ^ Mechoulam R, Brueggemeier RW, Denlinger DL, R.; Brueggemeier, R. W.; Denlinger, D. L. (September 1984). "Estrogens in insects". Journal Cellular and Molecular Life Sciences 40 (9): 942–944. doi:10.1007/BF01946450. 
  10. ^ a b Swaab DF, Garcia-Falgueras A (2009). "Sexual differentiation of the human brain in relation to gender identity and sexual orientation.". Funct. Neurol. 24 (1): 17–28. PMID 19403051. 
  11. ^ Browne KR (2002). Biology at work: rethinking sexual equality. New Brunswick, N.J: Rutgers University Press. p. 112. ISBN 0-8135-3053-9. http://books.google.com/books?id=vq_0BUkcZ5MC&lpg=PP1&dq=Biology%20at%20Work%3A%20Rethinking%20Sexual%20Equality&pg=PA112#v=onepage&q&f=false. 
  12. ^ Forest MG, Cathiard AM, Bertrand JA (July 1973). "Evidence of testicular activity in early infancy". J. Clin. Endocrinol. Metab. 37 (1): 148–51. doi:10.1210/jcem-37-1-148. PMID 4715291. 
  13. ^ Corbier P, Edwards DA, Roffi J (1992). "The neonatal testosterone surge: a comparative study". Arch Int Physiol Biochim Biophys 100 (2): 127–31. doi:10.3109/13813459209035274. PMID 1379488. 
  14. ^ Dakin CL, Wilson CA, Kalló I, Coen CW, Davies DC (May 2008). "Neonatal stimulation of 5-HT(2) receptors reduces androgen receptor expression in the rat anteroventral periventricular nucleus and sexually dimorphic preoptic area". Eur. J. Neurosci. 27 (9): 2473–80. doi:10.1111/j.1460-9568.2008.06216.x. PMID 18445234. 
  15. ^ http://homepage.psy.utexas.edu/homepage/class/psy308/Humm/ReviewofSexualDifferentiation
  16. ^ a b Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, Casaburi R (July 1996). "The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men". N. Engl. J. Med. 335 (1): 1–7. doi:10.1056/NEJM199607043350101. PMID 8637535. 
  17. ^ Mehta PH, Jones AC, Josephs RA (June 2008). "The social endocrinology of dominance: basal testosterone predicts cortisol changes and behavior following victory and defeat". J Pers Soc Psychol 94 (6): 1078–93. doi:10.1037/0022-3514.94.6.1078. PMID 18505319. http://homepage.psy.utexas.edu/homepage/faculty/josephs/pdf_documents/index.cfm.pdf. 
  18. ^ Ajayi AA, Halushka PV (May 2005). "Castration reduces platelet thromboxane A2 receptor density and aggregability". QJM 98 (5): 349–56. doi:10.1093/qjmed/hci054. PMID 15820970. 
  19. ^ Ajayi AA, Mathur R, Halushka PV (June 1995). "Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses". Circulation 91 (11): 2742–7. PMID 7758179. 
  20. ^ Morgentaler A, Schulman C (2009). "Testosterone and prostate safety". Front Horm Res. Frontiers of Hormone Research 37: 197–203. doi:10.1159/000176054. ISBN 978-3-8055-8622-1. PMID 19011298. 
  21. ^ Rhoden, E.L., M.A. Averbeck, and P.E. Teloken (2008). "Androgen replacement in men undergoing treatment for prostate cancer". J Sex Med 5 (9): 2202–8. doi:10.1111/j.1743-6109.2008.00925.x. PMID 18638000. 
  22. ^ Morgentaler, A. and A.M. Traish (2009). "Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth". Eur Urol 55 (2): 310–20. doi:10.1016/j.eururo.2008.09.024. PMID 18838208. 
  23. ^ Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Boloña ER, Sideras K, Uraga MV, Erwin PJ, Montori VM (January 2007). "Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials". Mayo Clin. Proc. 82 (1): 29–39. doi:10.4065/82.1.29. PMID 17285783. 
  24. ^ Jones TH, Saad F (April 2009). "The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process". Atherosclerosis 207 (2): 318–27. doi:10.1016/j.atherosclerosis.2009.04.016. PMID 19464009. 
  25. ^ Stanworth RD, Jones TH (2008). "Testosterone for the aging male; current evidence and recommended practice". Clin Interv Aging 3 (1): 25–44. PMC 2544367. PMID 18488876. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2544367. 
  26. ^ Mehta PH, Josephs RA (December 2006). "Testosterone change after losing predicts the decision to compete again". Horm Behav 50 (5): 684–92. doi:10.1016/j.yhbeh.2006.07.001. PMID 16928375. 
  27. ^ Marazziti D, Canale D (August 2004). "Hormonal changes when falling in love". Psychoneuroendocrinology 29 (7): 931–6. doi:10.1016/j.psyneuen.2003.08.006. PMID 15177709. 
  28. ^ Marazziti D, Canale D (August 2004). "Hormonal changes when falling in love". Psychoneuroendocrinology 29 (7): 931–6. doi:10.1016/j.psyneuen.2003.08.006. PMID 15177709. 
  29. ^ Sapienza P, Zingales L, Maestripieri D (September 2009). "Gender differences in financial risk aversion and career choices are affected by testosterone". Proc. Natl. Acad. Sci. U.S.A. 106 (36): 15268–73. Bibcode 2009PNAS..10615268S. doi:10.1073/pnas.0907352106. PMC 2741240. PMID 19706398. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2741240. 
  30. ^ Apicella CL, Dreber A, Campbell B, Gray PB, Hoffman M, Little AC (November 2008). "Testosterone and financial risk preferences". Evolution and Human Behavior 29 (6): 384–390. doi:10.1016/j.evolhumbehav.2008.07.001. 
  31. ^ Zak PJ, et al. (2009). Aleman, André. ed. "Testosterone Administration Decreases Generosity in the Ultimatum Game". PLoS ONE 4 (12): e8330. Bibcode 2009PLoSO...4.8330Z. doi:10.1371/journal.pone.0008330. PMC 2789942. PMID 20016825. http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0008330. 
  32. ^ Berg SJ, Wynne-Edwards KE (2001). "Changes in testosterone, cortisol, and estradiol levels in men becoming fathers". Mayo Clinic Proceedings 76 (1): 582–592. doi:10.4065/76.6.582. 
  33. ^ Booth A, Johnson DR, Granger DA (February 1999). "Testosterone and men's health". J Behav Med 22 (1): 1–19. doi:10.1023/A:1018705001117. PMID 10196726. Lay summary – CNN. 
  34. ^ Wilson JD (September 2001). "Androgens, androgen receptors, and male gender role behavior". Horm Behav 40 (2): 358–66. doi:10.1006/hbeh.2001.1684. PMID 11534997. 
  35. ^ Cosgrove, KP; Mazure CM, Staley JK (2007). "Evolving Knowledge of Sex Differences in Brain Structure, Function and Chemistry". Biol Psychiat 62 (8): 847–55. doi:10.1016/j.biopsych.2007.03.001. PMC 2711771. PMID 17544382. http://linkinghub.elsevier.com/retrieve/pii/S0006322307001989. 
  36. ^ Marner L, Nyengaard JR, Tang Y, Pakkenberg B. (2003). Marked loss of myelinated nerve fibers in the human brain with age. J Comp Neurol. 462(2):144-52. PubMed
  37. ^ Testosterone Affects Some Women's Career Choices
  38. ^ Hogervorst E, Bandelow S, Combrinck M, Smith AD (2004). "Low free testosterone is an independent risk factor for Alzheimer's disease". Exp. Gerontol. 39 (11–12): 1633–9. doi:10.1016/j.exger.2004.06.019. PMID 15582279. 
  39. ^ Moffat SD, Zonderman AB, Metter EJ, Kawas C, Blackman MR, Harman SM, Resnick SM (January 2004). "Free testosterone and risk for Alzheimer disease in older men". Neurology 62 (2): 188–93. PMID 14745052. 
  40. ^ Moffat SD, Hampson E (April 1996). "A curvilinear relationship between testosterone and spatial cognition in humans: possible influence of hand preference". Psychoneuroendocrinology 21 (3): 323–37. doi:10.1016/0306-4530(95)00051-8. PMID 8817730. 
  41. ^ a b Pike CJ, Rosario ER, Nguyen TV (April 2006). "Androgens, aging, and Alzheimer's disease". Endocrine 29 (2): 233–41. doi:10.1385/ENDO:29:2:233. PMID 16785599. 
  42. ^ a b Rosario ER, Chang L, Stanczyk FZ, Pike CJ (September 2004). "Age-related testosterone depletion and the development of Alzheimer disease". JAMA 292 (12): 1431–2. doi:10.1001/jama.292.12.1431-b. PMID 15383512. 
  43. ^ Wright J, Ellis L, Beaver K (2009). Handbook of crime correlates. San Diego: Academic Press. ISBN 0-12-373612-9. 
  44. ^ Soma, KK; Scotti, MA; Newman, AE; Charlier, TD; Demas, GE (2008). "Novel mechanisms for neuroendocrine regulation of aggression.". Frontiers in neuroendocrinology 29 (4): 476–89. doi:10.1016/j.yfrne.2007.12.003. PMID 18280561. 
  45. ^ Gettler LT, McDade TW, Feranil AB, Kuzawa CW (September 2011). "Longitudinal evidence that fatherhood decreases testosterone in human males". Proc Natl Acad Sci U S A 108 (39): 16194–9. doi:10.1073/pnas.1105403108. PMID 21911391. Lay summary – Northwestern University NewsCenter. 
  46. ^ Rohrmann, S.; Sutcliffe, C. G.; Bienstock, J. L.; Monsegue, D.; Akereyeni, F.; Bradwin, G.; Rifai, N.; Pollak, M. N. et al (2009). "Racial Variation in Sex Steroid Hormones and the Insulin-Like Growth Factor Axis in Umbilical Cord Blood of Male Neonates". Cancer Epidemiology Biomarkers & Prevention 18 (5): 1484–1491. doi:10.1158/1055-9965.EPI-08-0817. PMC 3012385. PMID 19423525. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3012385.  edit
  47. ^ McIntosh, H. (1997). "Why do African-American men suffer more prostate cancer?". JNCI Journal of the National Cancer Institute 89 (3): 188–189. doi:10.1093/jnci/89.3.188.  edit
  48. ^ Calistro Alvarado, L. (2010). "Population differences in the testosterone levels of young men are associated with prostate cancer disparities in older men". American Journal of Human Biology 22 (4): 449–455. doi:10.1002/ajhb.21016. PMID 20087895.  edit
  49. ^ a b de Kruif P (1945). The Male Hormone. New York: Harcourt, Brace. 
  50. ^ Myers JB, Meacham RB (2003). "Androgen Replacement Therapy in the Aging Male". Rev Urol 5 (4): 216–26. PMC 1508369. PMID 16985841. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1508369. 
  51. ^ a b Davis SR, Moreau M, Kroll R, Bouchard C, Panay N, Gass M, Braunstein GD, Hirschberg AL, Rodenberg C, Pack S, Koch H, Moufarege A, Studd J (November 2008). "Testosterone for low libido in postmenopausal women not taking estrogen". N. Engl. J. Med. 359 (19): 2005–17. doi:10.1056/NEJMoa0707302. PMID 18987368. 
  52. ^ "Testosterone replacement therapy for male aging: ASA position statement". J. Androl. 27 (2): 133–4. 2006. PMID 16474019. 
  53. ^ Guay AT, Spark RF, Bansal S, Cunningham GR, Goodman NF, Nankin HR, Petak SM, Perez JB (2003). "American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple's problem—2003 update". Endocr Pract 9 (1): 77–95. PMID 12917096. http://www.aace.com/pub/pdf/guidelines/sexdysguid.pdf. 
  54. ^ Holt EH, Zieve D (2008-03-18). "Testosterone". MedlinePlus Medical Encyclopedia. U.S. National Library of Medicine. http://www.nlm.nih.gov/MEDLINEPLUS/ency/article/003707.htm. Retrieved 2009-07-17. 
  55. ^ "Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility". Lancet 336 (8721): 955–9. October 1990. doi:10.1016/0140-6736(90)92416-F. PMID 1977002. 
  56. ^ Traish AM, Saad F, Guay A (2009). "The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance". J. Androl. 30 (1): 23–32. doi:10.2164/jandrol.108.005751. PMID 18772488. 
  57. ^ Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, Aleman A, Lock TM, Bosch JL, Grobbee DE, van der Schouw YT (January 2008). "Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial". JAMA 299 (1): 39–52. doi:10.1001/jama.2007.51. PMID 18167405. 
  58. ^ Cunningham GR (2008-06-25). "Testosterone treatment in aging men". EndocrineToday.com. http://www.endocrinetoday.com/view.aspx?rid=29171. Retrieved 2009-07-17. 
  59. ^ "Anabolic Steroid Control Act". United States Sentencing Commission. 1990. http://www.ussc.gov/USSCsteroidsreport-0306.pdf#search=%22Anabolic%20Steroid%20Control%20Act%20of%201990%22. 
  60. ^ Strahm E, Emery C, Saugy M, Dvorak J, Saudan C (December 2009). "Detection of testosterone administration based on the carbon isotope ratio profiling of endogenous steroids: international reference populations of professional soccer players". Br J Sports Med 43 (13): 1041–4. doi:10.1136/bjsm.2009.058669. PMC 2784500. PMID 19549614. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2784500. 
  61. ^ Kicman AT, Cowan DA (January 2009). "Subject-based profiling for the detection of testosterone administration in sport". Drug Test Anal 1 (1): 22–4. doi:10.1002/dta.14. PMID 20355155. 
  62. ^ Pozo OJ, Deventer K, Van Eenoo P, et al. Quantification of testosterone undecanoate in human hair by liquid chromatography-tandem mass spectrometry. Biomed. Chromatogr. 23: 873–880, 2009.
  63. ^ Baselt RC (2008). Disposition of Toxic Drugs & Chemicals in Man (8th ed.). Foster City, Calif: Biomedical Publications. pp. 1501–1504. ISBN 978-0-9626523-7-0. 
  64. ^ "Testosterone Information". Drugs.com. http://www.drugs.com/testosterone.html. 
  65. ^ "Striant Official FDA information, side effects and uses.". Drugs.com. http://www.drugs.com/pro/striant.html. 
  66. ^ "AndroGel Official FDA information, side effects and uses.". Drugs.com. http://www.drugs.com/pro/androgel.html. 
  67. ^ "Testim (patches and gel) medical facts". Drugs.com. http://www.drugs.com/mtm/testim-patches-and-gel.html. 
  68. ^ "Testopel Pellets". www.slatepharma.com. http://www.slatepharma.com/wp-content/uploads/2008/12/testopelpi.pdf. 
  69. ^ Waterman MR, Keeney DS (1992). "Genes involved in androgen biosynthesis and the male phenotype". Horm. Res. 38 (5–6): 217–21. doi:10.1159/000182546. PMID 1307739. 
  70. ^ Zuber MX, Simpson ER, Waterman MR (December 1986). "Expression of bovine 17 alpha-hydroxylase cytochrome P-450 cDNA in nonsteroidogenic (COS 1) cells". Science 234 (4781): 1258–61. Bibcode 1986Sci...234.1258Z. doi:10.1126/science.3535074. PMID 3535074. 
  71. ^ http://www.ncbi.nlm.nih.gov/pubmed/15507105
  72. ^ Brooks RV (November 1975). "Androgens". Clin Endocrinol Metab 4 (3): 503–20. PMID 58744. 
  73. ^ Payne AH, O'Shaughnessy P (1996). "Structure, function, and regulation of steroidogenic enzymes in the Leydig cell". In Payne AH, Hardy MP, Russell LD. Leydig Cell. Vienna [Il]: Cache River Press. pp. 260–285. ISBN 0-9627422-7-9. 
  74. ^ Swerdloff RS, Wang C, Bhasin S (April 1992). "Developments in the control of testicular function". Baillieres Clin. Endocrinol. Metab. 6 (2): 451–83. doi:10.1016/S0950-351X(05)80158-2. PMID 1377467. 
  75. ^ Håkonsen LB, Thulstrup AM, Aggerholm AS, Olsen J, Bonde JP, Andersen CY, Bungum M, Ernst EH, Hansen ML, Ernst EH, Ramlau-Hansen CH (2011). "Does weight loss improve semen quality and reproductive hormones? Results from a cohort of severely obese men". Reprod Health 8: 24. doi:10.1186/1742-4755-8-24. PMC 3177768. PMID 21849026. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3177768. 
  76. ^ Pilz S, Frisch S, Koertke H, Kuhn J, Dreier J, Obermayer-Pietsch B, Wehr E, Zittermann A (March 2011). "Effect of vitamin D supplementation on testosterone levels in men". Horm. Metab. Res. 43 (3): 223–5. doi:10.1055/s-0030-1269854. PMID 21154195. 
  77. ^ Prasad AS, Mantzoros CS, Beck FW, Hess JW, Brewer GJ (May 1996). "Zinc status and serum testosterone levels of healthy adults". Nutrition 12 (5): 344–8. doi:10.1016/S0899-9007(96)80058-X. PMID 8875519. 
  78. ^ Koehler K, Parr MK, Geyer H, Mester J, Schänzer W (January 2009). "Serum testosterone and urinary excretion of steroid hormone metabolites after administration of a high-dose zinc supplement". Eur J Clin Nutr 63 (1): 65–70. doi:10.1038/sj.ejcn.1602899. PMID 17882141. 
  79. ^ Schultheiss OC, Campbell KL, McClelland DC (December 1999). "Implicit power motivation moderates men's testosterone responses to imagined and real dominance success". Horm Behav 36 (3): 234–41. doi:10.1006/hbeh.1999.1542. PMID 10603287. 
  80. ^ Liu PY, Pincus SM, Takahashi PY, Roebuck PD, Iranmanesh A, Keenan DM, Veldhuis JD (January 2006). "Aging attenuates both the regularity and joint synchrony of LH and testosterone secretion in normal men: analyses via a model of graded GnRH receptor blockade". Am. J. Physiol. Endocrinol. Metab. 290 (1): E34–E41. doi:10.1152/ajpendo.00227.2005. PMID 16339924. 
  81. ^ Andersen ML, Tufik S (October 2008). "The effects of testosterone on sleep and sleep-disordered breathing in men: its bidirectional interaction with erectile function". Sleep Med Rev 12 (5): 365–79. doi:10.1016/j.smrv.2007.12.003. PMID 18519168. http://www.sono.org.br/pdf/2008_Andersen_Sleep_Med_Rev.pdf. 
  82. ^ Marin DP, Figueira AJ Junior, Pinto LG. "One session of resistance training may increase serum testosterone and triiodetironine in young men". Medicine & Science in Sports & Exercise 38 (5): S285. http://journals.lww.com/acsm-msse/Fulltext/2006/05001/One_Session_of_Resistance_Training_May_Increase.2108.aspx. 
  83. ^ Hulmi JJ, Ahtiainen JP, Selänne H, Volek JS, Häkkinen K, Kovanen V, Mero AA (May 2008). "Androgen receptors and testosterone in men—effects of protein ingestion, resistance exercise and fiber type". J. Steroid Biochem. Mol. Biol. 110 (1–2): 130–7. doi:10.1016/j.jsbmb.2008.03.030. PMID 18455389. 
  84. ^ Josephs RA, Guinn JS, Harper ML, Askari F (November 2001). "Liquorice consumption and salivary testosterone concentrations". Lancet 358 (9293): 1613–4. doi:10.1016/S0140-6736(01)06664-8. PMID 11716893. 
  85. ^ Armanini D, Mattarello MJ, Fiore C, Bonanni G, Scaroni C, Sartorato P, Palermo M (2004). "Licorice reduces serum testosterone in healthy women". Steroids 69 (11–12): 763–6. doi:10.1016/j.steroids.2004.09.005. PMID 15579328. 
  86. ^ Akdoğan M, Tamer MN, Cüre E, Cüre MC, Köroğlu BK, Delibaş N (May 2007). "Effect of spearmint (Mentha spicata Labiatae) teas on androgen levels in women with hirsutism". Phytother Res 21 (5): 444–7. doi:10.1002/ptr.2074. PMID 17310494. 
  87. ^ Kumar V, Kural MR, Pereira BM, Roy P (December 2008). "Spearmint induced hypothalamic oxidative stress and testicular anti-androgenicity in male rats – altered levels of gene expression, enzymes and hormones". Food Chem. Toxicol. 46 (12): 3563–70. doi:10.1016/j.fct.2008.08.027. PMID 18804513. 
  88. ^ Grant P (February 2010). "Spearmint herbal tea has significant anti-androgen effects in polycystic ovarian syndrome. A randomized controlled trial". Phytother Res 24 (2): 186–8. doi:10.1002/ptr.2900. PMID 19585478. 
  89. ^ Randall VA (April 1994). "Role of 5 alpha-reductase in health and disease". Baillieres Clin. Endocrinol. Metab. 8 (2): 405–31. doi:10.1016/S0950-351X(05)80259-9. PMID 8092979. 
  90. ^ Meinhardt U, Mullis PE (August 2002). "The essential role of the aromatase/p450arom". Semin. Reprod. Med. 20 (3): 277–84. doi:10.1055/s-2002-35374. PMID 12428207. 
  91. ^ Trager L (1977) (in German). Steroidhormone: Biosynthese, Stoffwechsel, Wirkung. Springer-Verlag. p. 349. ISBN 0-3870-8012-0. 
  92. ^ Hiipakka RA, Liao S (October 1998). "Molecular mechanism of androgen action". Trends Endocrinol. Metab. 9 (8): 317–24. doi:10.1016/S1043-2760(98)00081-2. PMID 18406296. 
  93. ^ McPhaul MJ, Young M (September 2001). "Complexities of androgen action". J. Am. Acad. Dermatol. 45 (3 Suppl): S87–94. doi:10.1067/mjd.2001.117429. PMID 11511858. 
  94. ^ Breiner M, Romalo G, Schweikert HU (August 1986). "Inhibition of androgen receptor binding by natural and synthetic steroids in cultured human genital skin fibroblasts". Klin. Wochenschr. 64 (16): 732–7. doi:10.1007/BF01734339. PMID 3762019. 
  95. ^ a b Bratoeff E, Cabeza M, Ramirez E, Heuze Y, Flores E (2005). "Recent advances in the chemistry and pharmacological activity of new steroidal antiandrogens and 5 alpha-reductase inhibitors". Curr. Med. Chem. 12 (8): 927–43. doi:10.2174/0929867053507306. PMID 15853706. 
  96. ^ Engel JB, Schally AV (February 2007). "Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone". Nat Clin Pract Endocrinol Metab 3 (2): 157–67. doi:10.1038/ncpendmet0399. PMID 17237842. 
  97. ^ Gould DC, Petty R (August 2000). "The male menopause: does it exist?: For: Some men need investigation and testosterone treatment". West. J. Med. 173 (2): 76–8. doi:10.1136/ewjm.173.2.76. PMC 1070997. PMID 10924412. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1070997. 
  98. ^ Berthold AA (1849). "Transplantation der Hoden [Transplantation of testis]" (in German). Arch. Anat. Physiol. Wissensch. 16: 42–6. 
  99. ^ Brown-Sequard CE (1889). "The effects produced on man by subcutaneous injections of liquid obtained from the testicles of animals". Lancet 2 (3438): 105. doi:10.1016/S0140-6736(00)64118-1. 
  100. ^ Gallagher TF, Koch FC (November 1929). "The testicular horomone". J. Biol. Chem. 84 (2): 495–500. 
  101. ^ David KG., Dingemanse E, Freud J. Laqueur E (May 1935). "Über krystallinisches mannliches Hormon aus Hoden (Testosteron) wirksamer als aus harn oder aus Cholesterin bereitetes Androsteron [On crystalline male hormone from testicles (testosterone) effective as from urine or from cholesterol]" (in German). Hoppe Seylers Z Physiol Chem 233 (5–6): 281. doi:10.1515/bchm2.1935.233.5-6.281. 
  102. ^ Butenandt A, Hanisch G (1935). "Umwandlung des Dehydroandrosterons in Androstendiol und Testosterone; ein Weg zur Darstellung des Testosterons aus Cholestrin [About Testosterone. Conversion of Dehydro-androsterons into androstendiol and testosterone; a way for the structure assignment of testosterone from cholestrol]" (in German). Hoppe Seylers Z Physiol Chem 237 (2): 89. doi:10.1515/bchm2.1935.237.1-3.89. 
  103. ^ a b Freeman ER, Bloom DA, McGuire EJ (February 2001). "A brief history of testosterone". J. Urol. 165 (2): 371–3. doi:10.1097/00005392-200102000-00004. PMID 11176375. 
  104. ^ Butenandt A, Hanisch G (1935). "Uber die Umwandlung des Dehydroandrosterons in Androstenol-(17)-one-(3) (Testosterone); um Weg zur Darstellung des Testosterons auf Cholesterin (Vorlauf Mitteilung). [The conversion of dehydroandrosterone into androstenol-(17)-one-3 (testosterone); a method for the production of testosterone from cholesterol (preliminary communication)]" (in German). Chemische Berichte 68: 1859–1862. 
  105. ^ Ruzicka L, Wettstein A (1935). "Uber die kristallinische Herstellung des Testikelhormons, Testosteron (Androsten-3-ol-17-ol) [The crystalline production of the testicle hormone, testosterone (Androsten-3-ol-17-ol]" (in German). Helvetica Chimica Acta 18: 1264–1275. doi:10.1002/hlca.193501801176. 
  106. ^ Hoberman JM, Yesalis CE (February 1995). "The history of synthetic testosterone". Sci. Am. 272 (2): 76–81. doi:10.1038/scientificamerican0295-76. PMID 7817189. 
  107. ^ Kenyon AT, Knowlton K, Sandiford I, Koch FC, Lotwin,G (February 1940). "A comparative study of the metabolic effects of testosterone propionate in normal men and women and in eunuchoidism". Endocrinology 26 (1): 26–45. doi:10.1210/Endo-26-1-26. 
  108. ^ Schwarz S, Onken D, Schubert A (July 1999). "The steroid story of Jenapharm: from the late 1940s to the early 1970s". Steroids 64 (7): 439–45. doi:10.1016/S0039-128X(99)00003-3. PMID 10443899. http://www.ingentaconnect.com/content/els/0039128x/1999/00000064/00000007/art00003. 
  109. ^ Travison TG, Araujo AB, O'Donnell AB, Kupelian V, McKinlay JB (January 2007). "A population-level decline in serum testosterone levels in American men". J. Clin. Endocrinol. Metab. 92 (1): 196–202. doi:10.1210/jc.2006-1375. PMID 17062768. 
  110. ^ Dindyal S (2007). "The sperm count has been decreasing steadily for many years in Western industrialised countries: Is there an endocrine basis for this decrease?". The Internet Journal of Urology 2 (1): 1–21. http://www.ispub.com/ostia/index.php?xmlFilePath=journals/iju/vol2n1/sperm.xml. 
  111. ^ Bhasin S (January 2007). "Secular decline in male reproductive function: Is manliness threatened?". J. Clin. Endocrinol. Metab. 92 (1): 44–5. doi:10.1210/jc.2006-2438. PMID 17209224. 

Translations:

Testosterone

Top

Dansk (Danish)
n. - testosteron (mandligt kønshormon)

Nederlands (Dutch)
testosteron

Français (French)
n. - testostérone

Deutsch (German)
n. - Testosteron

Ελληνική (Greek)
n. - (βιολ.) τεστοστερόνη

Italiano (Italian)
testosterone

Português (Portuguese)
n. - testosterona (f)

Русский (Russian)
тестостерон (мужской половой гормон)

Español (Spanish)
n. - testosterona

Svenska (Swedish)
n. - testosteron (manligt könshormon)

中文(简体)(Chinese (Simplified))
睾丸激素

中文(繁體)(Chinese (Traditional))
n. - 睾丸激素

한국어 (Korean)
n. - 테스토스테론(남성 호르몬)

日本語 (Japanese)
n. - テストステロン

العربيه (Arabic)
‏(الاسم) هرمون تفرزه الخصيه‏

עברית (Hebrew)
n. - ‮הורמון זכרות‬


 
 

 

Copyrights:

American Heritage Dictionary. The American Heritage® Dictionary of the English Language, Fourth Edition Copyright © 2007, 2000 by Houghton Mifflin Company. Updated in 2009. Published by Houghton Mifflin Company. All rights reserved.  Read more
Britannica Concise Encyclopedia. Britannica Concise Encyclopedia. © 1994-2012 Encyclopædia Britannica, Inc. All rights reserved.  Read more
$copyright.smallImage.alttext Gale Encyclopedia of Cancer. Gale Encyclopedia of Cancer. Copyright © 2006 by The Gale Group, Inc. All rights reserved.  Read more
Oxford Food & Fitness Dictionary. Food and Fitness: A Dictionary of Diet and Exercise. Copyright © 1997, 2003 by Oxford University Press. All rights reserved.  Read more
Oxford Companion to the Body. The Oxford Companion to the Body. Copyright © 2001, 2003 by Oxford University Press. All rights reserved.  Read more
Drug Info. Gold Standard. Copyright © 2008 by Gold Standard. All rights reserved.  Read more
 Oxford A-Z of Medicinal Drugs. Market University Press. © 2000, 2003, 2010 An A-Z of Medicinal Drugs. All rights reserved.  Read more
Oxford Dictionary of Sports Science & Medicine. The Oxford Dictionary of Sports Science & Medicine. Copyright © Michael Kent 1998, 2006, 2007. All rights reserved.  Read more
Columbia Encyclopedia. The Columbia Electronic Encyclopedia, Sixth Edition Copyright © 2012, Columbia University Press. Licensed from Columbia University Press. All rights reserved. www.cc.columbia.edu/cu/cup/ Read more
Dictionary of Cultural Literacy: Health. The New Dictionary of Cultural Literacy, Third Edition Edited by E.D. Hirsch, Jr., Joseph F. Kett, and James Trefil. Copyright © 2002 by Houghton Mifflin Company. Published by Houghton Mifflin. All rights reserved.  Read more
 Oxford Dictionary of Biochemistry. Oxford University Press. Oxford Dictionary of Biochemistry and Molecular Biology © 1997, 2000, 2006 All rights reserved.  Read more
Saunders Veterinary Dictionary. Saunders Comprehensive Veterinary Dictionary 3rd Edition. Copyright © 2007 by D.C. Blood, V.P. Studdert and C.C. Gay, Elsevier. All rights reserved.  Read more
Random House Word Menu. © 2010 Write Brothers Inc. Word Menu is a registered trademark of the Estate of Stephen Glazier. Write Brothers Inc. All rights reserved.  Read more
 Rhymes. Oxford University Press. © 2006, 2007 All rights reserved.  Read more
Wikipedia on Answers.com. This article is licensed under the Creative Commons Attribution/Share-Alike License. It uses material from the Wikipedia article Testosterone Read more
Translations. Copyright © 2007, WizCom Technologies Ltd. All rights reserved.  Read more

Follow us
Facebook Twitter
YouTube